This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
10 Nov 2014

New Drug for Common Liver Disease Improves Liver Health

An experimental drug aimed at treating a common liver disease showed promising results and potential problems in a multicenter clinical trial funded by the National Institutes of Health. The FLINT study found that people with nonalcoholic steatohepatitis (NASH) who took obeticholic acid (OCA) had improved liver health during that period, including decreased inflammation and fat in the liver and decreased body weight versus people receiving a placebo. OCA was also associated with increases in itching and total cholesterol.

 

The findings of FLINT, or the Farnesoid X Receptor Ligand Obeticholic Acid in NASH Treatment Trial, were published online Nov. 6 in The Lancet  External Web Site Policy. FLINT was sponsored by the NIH’s National Institute of Diabetes and Digestive and Kidney Diseases.

 

“NASH is a common and potentially serious disease that currently has no approved treatment. Management typically includes weight loss through diet and exercise,” said Averell Sherker, NIDDK programme official for the NASH Clinical Research Network (NASH CRN), which performed the FLINT study.

 

Liver health improved in 45% of people on OCA versus 21% of the placebo group. “Although obeticholic acid did not eliminate liver disease in FLINT participants, it demonstrated a promising effect. Larger studies will be required to determine the drug’s safety and efficacy,” Sherker said.

 

FLINT enrolled 283 people at eight centers across the country. At the study’s start, participants were 18 and older and had been diagnosed with definite or borderline NASH. They were randomly assigned to one of two groups: one took 25 mg of OCA daily and one received a placebo that resembled the OCA pill. The study was double-blinded, so neither participants nor investigators knew which person was in which group.

 

Trial investigators intended for the groups to receive the drug or placebo for 72 weeks, with an additional 24 weeks of follow-up off treatment. However, planned interim analysis for safety and efficacy showed that OCA had significant beneficial effects on NASH-related liver health.

 

The analysis also found unanticipated increases in total cholesterol in the OCA group. They had increased LDL cholesterol (“bad” cholesterol) and decreased HDL cholesterol (“good” cholesterol) — notable because NASH patients are already at higher risk for cardiovascular diseases. As cholesterol treatment was not standardised as part of the study, further research is needed to fully understand the potential effect of OCA on cholesterol.

 

Because of both factors, and with the concurrence of the Data Safety and Monitoring Board, NIDDK decided to stop treatment but continue the study, move all patients into the follow-up phase, and perform no additional liver biopsies — which carry their own risks. Adverse cholesterol increases were not sustained after stopping OCA.

 

“The FLINT trial represents an important advance in the search for treatments of NASH. The causes of NASH are not fully understood, and causes and treatments may be different among patients,” said the study’s lead author, Brent Neuschwander-Tetri, a professor at St. Louis University. “We need to study the changes in cholesterol levels more to know if the increases caused by obeticholic acid increase the risk of hardening of the arteries. We found that the improvement in liver enzymes with obeticholic acid were not sustained after treatment was stopped, so we would expect that treatment would need to be indefinite, much like the medications for diabetes and hypertension.”

Related News